Accellta

Company Overview

Snapshot

Founded in November 2012, Accellta operates with 11–50 employees, focusing on industrial-scale stem cell culturing. The company has secured funding across three rounds from Horizons Ventures and AMIT-Technion. In January 2024, Accellta received a grant from the Israel Innovation Authority.

Business overview

Accellta specializes in the large-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells. The company's core technology utilizes 3D carrier-free suspension systems under feeder-free, adherent-free, and xeno-free conditions to optimize production efficiency and reduce costs while maintaining consistent quality. Accellta's products are used in cell banking, drug discovery, regenerative medicine, and scientific research, serving markets within the Health Tech & Life Sciences sector, particularly in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In January 2024, Accellta received a grant from the Israel Innovation Authority. This grant signals continued governmental validation and support for Accellta's innovative approach to stem cell culturing, reinforcing its potential for advancing biotechnological applications and commercialization within the life sciences industry.

Company Intelligence Q&A

What is Accellta's primary focus?

Accellta specializes in the industrial-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells for research and medicine.

When was Accellta founded?

Accellta was founded in November 2012.

What was a significant recent development for Accellta?

In January 2024, Accellta received a grant from the Israel Innovation Authority.

Which organizations have partnered with Accellta for technology licensing?

In March 2018, Hitachi Chemical licensed stem cell technology from Accellta. In June 2015, Accellta granted rights for its feeder-free stem cell culture medium to Thermo Fisher Scientific.

What was Accellta's collaboration with Nano Dimension?

In May 2016, Nano Dimension and Accellta joined forces to successfully bioprint stem cell-derived tissues.